Clinical Review : The Guillain-Barré Syndrome in Childhood

Markland, L; Riley, Harris D.

doi:10.1177/000992286700600314

Cited by 26 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[5][6][7][8][9][10][11][12][13][14] The children with Guillain-Barré syndrome not given intravenous immunoglobulin were analyzed.…”

Section: Methodsmentioning

confidence: 99%

“…Our study analyzed the outcome of patients who received intravenous immunoglobulin (prospective study) and compared it with those who were not treated with intravenous immunoglobulin in the Sultanate and elsewhere from available studies in medical literature. [5][6][7][8][9][10][11][12][13][14] In addition, the relapse rate was identified and management of Guillain-Barré syndrome was suggested.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Ten-Year Prospective Study (Clinical Spectrum) of Childhood Guillain-Barré Syndrome in the Arabian Peninsula: Comparison of Outcome in Patients in the Pre— and Post—Intravenous Immunoglobulin Eras

et al. 2003

View full text Add to dashboard Cite

A prospective study of Guillain-Barré syndrome from January 1992 to December 2001 was undertaken. Intravenous immunoglobulins were used in all patients. All patients were followed up until complete recovery. Various parameters, such as onset of weakness, duration of hospital stay, ventilation requirement, residual deficit, and mortality, were recorded. Acute relapses and fluctuations were also noted. The pattern of this group was compared with patients before 1992, who were not given intravenous immunoglobulins in the Sultanate of Oman. Our data were compared with a few studies prior to 1992 from the medical literature. Our study revealed a definite benefit with intravenous immunoglobulins. The disease course and hospital stay were shortened. Fewer patients needed ventilation. There was no mortality, and the residual deficit was less than 5%. Occasional relapses at a later stage in the course of illness have been noted in acute Guillain-Barré syndrome. However, acute relapse, a new phenomenon that was not seen in the pre-intravenous immunoglobulin era, stood at 11.9%. Intravenous immunoglobulins have made a significant difference in the outcome of Guillain-Barré syndrome, but one has to be aware of acute relapses, which usually occur in the first 2 to 3 weeks after administration.

show abstract

“…[5][6][7][8][9][10][11][12][13][14] The children with Guillain-Barré syndrome not given intravenous immunoglobulin were analyzed.…”

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

Ten-Year Prospective Study (Clinical Spectrum) of Childhood Guillain-Barré Syndrome in the Arabian Peninsula: Comparison of Outcome in Patients in the Pre— and Post—Intravenous Immunoglobulin Eras

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Affected children usually recover in shorter time than adult, while the mortality rate was reported at 3-5%. [89]…”

Section: Introductionmentioning

confidence: 99%

Spectrum of Guillain-Barré syndrome in tertiary care hospital at Kolkata

et al. 2011

View full text Add to dashboard Cite

Objective:In childhood Guillain–Barré syndrome (GBS), the clinical profiles using intravenous immunoglobulin (IVIg) in addition to supportive care were studied.Materials and Methods:This was a retrospective analysis of 139 children with severe GBS admitted to our respiratory care unit managed with the IVIg as an adjunct intervention to conventional supportive and respiratory care.Results:In our case series of 139 cases, motor weakness was the most common presenting feature. Antecedent illness was found in 66.7% of cases in the preceding two weeks, which included nonspecific illness, acute respiratory infection, diarrhea, and chickenpox. At onset, sensory symptoms (pain and paresthesia) were noted in 59% of the cases and limb weakness in 77%. On admission, a majority (61.54%) were in Hughes neurological disability grading stage V; all had limb weakness at the peak deficit, autonomic disturbance was seen in 35.8%, and bulbar palsy in 52%. Duration of illness was less than three weeks in 67% of cases. The mean duration of ventilation was 21.5 days (range, 5-60 days).Conclusions:Male preponderance and motor weakness was the most common presenting illness and a majority achieved full recovery in our series. Although IVIg may be useful in the treatment of GBS, the key issue is excellent intensive care unit management.

show abstract

“…Affected adult patients usually recover in longer time than children, while the mortality rate was reported at 3-5%. [8,9] We performed a prospective study on the natural history with GBS to study their clinical profile using intravenous immunoglobulin (IVIg) in addition to supportive care.…”

Section: Original Research Articlementioning

confidence: 99%

Guillain-Barre, Syndrome: Clinical Profile

Manju

Kapoor

Dogra

et al. 2019

CMRO

View full text Add to dashboard Cite

Guillain-Barré Syndrome (GBS) is an acute, immune-mediated polyradiculoneuropathy and an important cause of acute flaccid paralysis (AFP) worldwide. Respiratory insufficiency requiring v entilator occurs in 30% of patients that prolong the hospital stay, leading to morbidity and mortality. There had been relatively few studies of Guillain-Barresyndrome in adults from North India. Objective : To evaluate clinical profile, epidemiological, laboratory and electrodiagnostic feature of patients with Guillain Barre Syndrome in adults and use of intravenous immunoglobulin (IVIg) in addition to supportive care. Materials and Methods : This was a prospective study of 50 patients with GBS admitted to our medicine department in rural tertiary care institution Dr.RPGMC Tanda. We studied the epidemiological, clinical, electrophysiological features and their outcome. Result: In our study 50 cases were taken, motor weakness was the most common presenting feature. Antecedent illness was found in 48% of cases in the preceding two weeks, which included nonspecific illness, acute respiratory infection, diarrhea, and viral infection like chickenpox. At onset, sensory symptoms (pain and paresthesia) were noted in 16% of the cases and limb weakness in 77%. On admission, a majority (64%) was in Hughes neurological disability grading stage III-IV' all had limb weakness at the peak deficit; autonomic disturbance was seen in 35.8%, and bulbar palsy in 6%. Duration of illness was less than three weeks in 60% of cases. The one patient had undergone repiratory distress and kept on ventilator for 23 days and survived. Conclusions:Male preponderance and motor weakness was the most common presenting illness and a majority achieved full recovery in our study. Although IVIg may be useful in the treatment of GBS, the key issue is excellent intensive care unit management.

show abstract

Clinical Review : The Guillain-Barré Syndrome in Childhood

Cited by 26 publications

References 28 publications

Ten-Year Prospective Study (Clinical Spectrum) of Childhood Guillain-Barré Syndrome in the Arabian Peninsula: Comparison of Outcome in Patients in the Pre— and Post—Intravenous Immunoglobulin Eras

Ten-Year Prospective Study (Clinical Spectrum) of Childhood Guillain-Barré Syndrome in the Arabian Peninsula: Comparison of Outcome in Patients in the Pre— and Post—Intravenous Immunoglobulin Eras

Spectrum of Guillain-Barré syndrome in tertiary care hospital at Kolkata

Guillain-Barre, Syndrome: Clinical Profile

Contact Info

Product

Resources

About